PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Universität Hamburg · Heidelberg University · +3 more institutions
Abstract
PURPOSE: In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0.49 to 0.79; P
Citation impact
- FWCI
- 53.99
- Percentile
- 100%
- References
- 32
Authors
17- LPLuis Paz‐AresCorresponding
Universität Hamburg, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf, Nini Hospital
- FDFilippo de Marinis
Universität Hamburg, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf, Nini Hospital
- MDMircea Dediu
Universität Hamburg, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf, Nini Hospital
- MTMichael Thomas
Universität Hamburg, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf, Nini Hospital
- JPJean-Louis Pujol
Universität Hamburg, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf, Nini Hospital
Topics & keywords
- Pemetrexed
- Medicine
- Internal medicine
- Hazard ratio
- Placebo
- Lung cancer
- Oncology
- Maintenance therapy
- Good health and well-being